Lombardi director receives international award for research achievements

September 23, 2005

Washington, DC --Richard Pestell, MD, PhD, director of Georgetown's Lombardi Comprehensive Cancer Center, accepted the Endocrine Society of Australia's highest award, the Keith Harrison Plenary Lecture and Award, on Sept. 6 at the society's annual scientific meeting in Australia. The award recognizes discoveries on breast and prostate cancer in Pestell's lab at Georgetown University. He also delivered a lecture at Curtin University of Technology on new opportunities in cancer therapy during his visit.

"Dr. Pestell richly deserves this distinguished recognition because of his important fundamental contributions to our understanding of endocrinology and cancer, as well as his farsighted leadership of Georgetown's laboratories, research programs and our Lombardi Comprehensive Cancer Center," said Stuart Bondurant, MD, interim executive vice president for health sciences at Georgetown University.

Pestell, an internationally renowned expert in oncology and endocrinology, was named Lombardi's director in September 2002. He is a highly respected researcher and clinician whose current work is focused on developing new cancer therapies that specifically target tumors and reduce the side effects that are associated with commonly used cancer treatments such as chemotherapy and radiation.

Pestell's research concentrates on identifying molecular markers of pre-malignant disease to develop preventive approaches to cancer. He has made significant contributions to the understanding of cell cycle regulation and the disturbances that can lead to the malignant transformation of cells.

Pestell has particular expertise in hormonally-responsive tumors, including breast and prostate cancer, and his work is directed toward the discovery of novel therapies for these cancers.

The author of more than 220 research papers and reviews and 130 research abstracts, Pestell has consistently published in leading journals including Cell, Science and Nature Medicine. He has an outstanding record of obtaining funding, with current funding, including five NIH RO1 grants funded by the National Institutes of Health, totaling more than $20 million.
The Endocrine Society of Australia is a national non-profit organization of scientists and clinicians who conduct research and practice in the field of endocrinology.

The Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center and Georgetown University Hospital, seeks to improve the diagnosis, treatment and prevention of cancer through innovative basic and clinical research, patient care, community education and outreach, and the training of cancer specialists of the future. Lombardi is one of only 39 comprehensive cancer centers in the nation, as designated by the National Cancer Institute, and the only one in the Washington DC area. For more information, go to http://lombardi.georgetown.edu/

Georgetown University Medical Center

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.